Eastern Cooperative Oncology Group, phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity

Mark S. Talamonti*, Paul J. Catalano, David J. Vaughn, Richard Whittington, R. Danie Beauchamp, Jordan Berlin, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Purpose: We preformed a phase I trial of protracted venous infusion (PVI) fluorouracil (5-FU) plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer to determine the maximum-tolerated dose of gemcitabine that could be safely administered. We also sought to identify the toxicities associated with this treatment protocol. Patients and Methods: Seven patients with locally advanced pancreas cancer were treated with planned doses of radiation (59.4 Gy) and PVI of 5-FU (200 mg/m2/d) with gemcitabine doses of 50 to 100 mg/ m2/wk. Results: Two of three patients at the 100-mg/m2/wk dose level experienced dose-limiting toxicity (DLT), as did three of four at the 50-mg/m2/wk dose level. One patient experienced a mucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed chemotherapy. Three patients developed gastric or duodenal ulcers with severe bleeding requiring transfusion. One patient developed severe thrombocytopenia lasting longer than 4 weeks. Three of the five episodes of DLT developed at radiation doses ≤ 36 Gy. Conclusion: Based on this experience, we cannot recommend further investigation of regimens incorporating gemcitabine into regimens of radiation with PVI 5-FU. The mechanism of this synergistic toxicity remains to be determined. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)3384-3389
Number of pages6
JournalJournal of Clinical Oncology
Volume18
Issue number19
DOIs
StatePublished - Oct 1 2000

Fingerprint

gemcitabine
Pancreatic Neoplasms
Fluorouracil
Radiotherapy
Radiation
Radiation Dosage
Stevens-Johnson Syndrome
Maximum Tolerated Dose
Stomach Ulcer
Duodenal Ulcer
Clinical Protocols
Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{ff1e355c81494a0189062a63805da4bd,
title = "Eastern Cooperative Oncology Group, phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity",
abstract = "Purpose: We preformed a phase I trial of protracted venous infusion (PVI) fluorouracil (5-FU) plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer to determine the maximum-tolerated dose of gemcitabine that could be safely administered. We also sought to identify the toxicities associated with this treatment protocol. Patients and Methods: Seven patients with locally advanced pancreas cancer were treated with planned doses of radiation (59.4 Gy) and PVI of 5-FU (200 mg/m2/d) with gemcitabine doses of 50 to 100 mg/ m2/wk. Results: Two of three patients at the 100-mg/m2/wk dose level experienced dose-limiting toxicity (DLT), as did three of four at the 50-mg/m2/wk dose level. One patient experienced a mucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed chemotherapy. Three patients developed gastric or duodenal ulcers with severe bleeding requiring transfusion. One patient developed severe thrombocytopenia lasting longer than 4 weeks. Three of the five episodes of DLT developed at radiation doses ≤ 36 Gy. Conclusion: Based on this experience, we cannot recommend further investigation of regimens incorporating gemcitabine into regimens of radiation with PVI 5-FU. The mechanism of this synergistic toxicity remains to be determined. (C) 2000 by American Society of Clinical Oncology.",
author = "Talamonti, {Mark S.} and Catalano, {Paul J.} and Vaughn, {David J.} and Richard Whittington and Beauchamp, {R. Danie} and Jordan Berlin and {Benson III}, {Al B}",
year = "2000",
month = "10",
day = "1",
doi = "10.1200/JCO.2000.18.19.3384",
language = "English (US)",
volume = "18",
pages = "3384--3389",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

Eastern Cooperative Oncology Group, phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer : A regimen with unexpected early toxicity. / Talamonti, Mark S.; Catalano, Paul J.; Vaughn, David J.; Whittington, Richard; Beauchamp, R. Danie; Berlin, Jordan; Benson III, Al B.

In: Journal of Clinical Oncology, Vol. 18, No. 19, 01.10.2000, p. 3384-3389.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Eastern Cooperative Oncology Group, phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer

T2 - A regimen with unexpected early toxicity

AU - Talamonti, Mark S.

AU - Catalano, Paul J.

AU - Vaughn, David J.

AU - Whittington, Richard

AU - Beauchamp, R. Danie

AU - Berlin, Jordan

AU - Benson III, Al B

PY - 2000/10/1

Y1 - 2000/10/1

N2 - Purpose: We preformed a phase I trial of protracted venous infusion (PVI) fluorouracil (5-FU) plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer to determine the maximum-tolerated dose of gemcitabine that could be safely administered. We also sought to identify the toxicities associated with this treatment protocol. Patients and Methods: Seven patients with locally advanced pancreas cancer were treated with planned doses of radiation (59.4 Gy) and PVI of 5-FU (200 mg/m2/d) with gemcitabine doses of 50 to 100 mg/ m2/wk. Results: Two of three patients at the 100-mg/m2/wk dose level experienced dose-limiting toxicity (DLT), as did three of four at the 50-mg/m2/wk dose level. One patient experienced a mucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed chemotherapy. Three patients developed gastric or duodenal ulcers with severe bleeding requiring transfusion. One patient developed severe thrombocytopenia lasting longer than 4 weeks. Three of the five episodes of DLT developed at radiation doses ≤ 36 Gy. Conclusion: Based on this experience, we cannot recommend further investigation of regimens incorporating gemcitabine into regimens of radiation with PVI 5-FU. The mechanism of this synergistic toxicity remains to be determined. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: We preformed a phase I trial of protracted venous infusion (PVI) fluorouracil (5-FU) plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer to determine the maximum-tolerated dose of gemcitabine that could be safely administered. We also sought to identify the toxicities associated with this treatment protocol. Patients and Methods: Seven patients with locally advanced pancreas cancer were treated with planned doses of radiation (59.4 Gy) and PVI of 5-FU (200 mg/m2/d) with gemcitabine doses of 50 to 100 mg/ m2/wk. Results: Two of three patients at the 100-mg/m2/wk dose level experienced dose-limiting toxicity (DLT), as did three of four at the 50-mg/m2/wk dose level. One patient experienced a mucocutaneous reaction described as a Stevens-Johnson syndrome that was attributed chemotherapy. Three patients developed gastric or duodenal ulcers with severe bleeding requiring transfusion. One patient developed severe thrombocytopenia lasting longer than 4 weeks. Three of the five episodes of DLT developed at radiation doses ≤ 36 Gy. Conclusion: Based on this experience, we cannot recommend further investigation of regimens incorporating gemcitabine into regimens of radiation with PVI 5-FU. The mechanism of this synergistic toxicity remains to be determined. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=0034306137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034306137&partnerID=8YFLogxK

U2 - 10.1200/JCO.2000.18.19.3384

DO - 10.1200/JCO.2000.18.19.3384

M3 - Article

C2 - 11013279

AN - SCOPUS:0034306137

VL - 18

SP - 3384

EP - 3389

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -